Idiopathic pulmonary fibrosis biomarkers and methods of production and use thereof

Through the combination and immunoassay of biomarkers such as TIMP1, HA and PIIINP, combined with mathematical algorithms, the difficulties of IPF diagnosis and progress monitoring are solved, and the accurate identification and treatment evaluation of IPF in blood samples are achieved, providing more objective clinical decision-making support.

CN119032274APending Publication Date: 2024-11-26SIEMENS HEALTHCARE DIAGNOSTICS INC
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202380033687.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-20
Filing Date
2023-04-19
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The lack of reliable blood biomarkers for the diagnosis and progress monitoring of idiopathic pulmonary fibrosis (IPF) is a problem, resulting in difficulty in clinical prediction and difficulty in assessing therapeutic effects.

Method used

Using tissue metalloproteinase inhibitor 1 (TIMP1), hyaluronic acid (HA) and type III procollagen N-terminal propeptide (PIIINP) as biomarkers, IPF scores are calculated by immunoassays and mathematical algorithms to provide one or more Combination of biomarkers to assist in diagnostic and therapeutic decision-making.

Benefits of technology

It realizes accurate identification of the presence, severity and susceptibility of IPF in blood samples, provides prognostic information on disease course and mortality, reduces dependence on lung biopsy, and improves the objectivity and reliability of diagnosis and treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119032274A_ABST
    Figure CN119032274A_ABST
Patent Text Reader

Abstract

Methods of determining the presence, severity, and / or susceptibility of idiopathic pulmonary fibrosis (IPF) in an individual are disclosed. The method utilizes at least one diagnostic marker of the dynamic process of extracellular matrix synthesis and / or extracellular matrix degradation from the sample. The at least one diagnostic marker may be selected from the group consisting of tissue metalloproteinase inhibitor 1 (TIMP1), hyaluronic acid (HA), and / or type III procollagen N-terminal propeptide (PIIINP).
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority or the benefit of U.S. Provisional Patent Application No. 63 / 363,282, filed on April 20, 2022, under 35 U.S.C. §119, the contents of which are incorporated herein by reference in their entirety.

[0003] Sequence Listing

[0004] The sequences referred to herein are listed in the Sequence Listing, which is submitted as a 5KB ASCII text file entitled "biomarker_ST25a.xml" and was created on April 19, 2023, and is hereby incorporated by reference in its entirety. Background Art

[0005] Idiopathic pulmonary fibrosis (IPF) is a life-threatening fibrotic lung disease of unknown etiology that affects up to 185,000 individuals in the United States. There are currently no effective therapies for IPF, resulting in significant morbidity and mortality. The pathogenesis of IPF is not fully understood. Although IPF was initially believed to be caused by generalized lung inflammation leading to fibrosis, the current paradigm has shifted to alveolar epithelial cell dysfunction and dysregulated fibroplasia.

[0006] Although the median survival is 2-3 years, there is a broad spectrum of disease courses that can be summarized into three categories: stable or very slow decline, rapid deterioration, and stable periods interspersed with decline periods. Currently, it is difficult for clinicians to predict the disease course of individual patients because there are no recognized surrogates for these clinical courses.

[0007] Biomarkers serve as surrogate markers for clinically significant results and may or may not reflect the underlying pathogenesis of the disease. Examples of clinical applications include diagnosis, prediction of disease progression or regression, and prediction of mortality. Biomarkers should be easily accessible, reliably measured, and can be used for continuous monitoring. Ideally, it should also provide advantages over currently used clinical measures in terms of ease of use, time frame, and / or cost.

[0008] However, no reliable blood-based biomarkers have been identified as single biomarkers or combination biomarkers (based on blood, imaging or patient clinical data) that effectively aid in the diagnosis and progression of IPF.

[0009] Therefore, there is a need in the art for biomarkers and assays for IPF. The present disclosure is directed to such biomarkers, as well as compositions / devices / assays comprising reagents for measuring the biomarkers, and methods of use thereof. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] Embodiments of the present disclosure, briefly summarized above and discussed in more detail below, may be understood by reference to the illustrative embodiments of the present disclosure depicted in the accompanying drawings. However, the drawings illustrate only typical embodiments of the present disclosure and therefore should not be considered limiting of scope, as the present disclosure may admit of other equally effective embodiments.

[0012] Figure 1 A receiver operating characteristic curve (ROC) is graphically depicted illustrating the predictive value of the biomarker tissue inhibitor of metalloproteinases 1 (TIMP1) alone for identifying IPF in accordance with the present disclosure.

[0013] Figure 2 An exemplary block diagram of a computer system 1100 is depicted.

[0014] Figure 3 An exemplary flow diagram of method 1200 is depicted.

[0015] Figure 4 An exemplary flow diagram of method 1300 is depicted.

[0016] For ease of understanding, the same reference numerals have been used as much as possible to represent the same elements common to the drawings. The drawings are not drawn to scale and may be simplified for clarity. Elements and features of one embodiment may be beneficially incorporated into other embodiments without further description.

[0017] Detailed Description

[0018] Before explaining at least one embodiment of the present disclosure in detail through exemplary language and results, it should be understood that the present disclosure is not limited in its application to the construction details and component arrangements set forth in the following description. The present disclosure can have other embodiments, or can be practiced or carried out in various ways. Therefore, the language used herein is intended to give the widest possible scope and meaning; and the embodiments are intended to be exemplary-not exhaustive. In addition, it should be understood that the words and terms used herein are for descriptive purposes and should not be considered restrictive.

[0019] Unless otherwise defined herein, the scientific and technical terms used in conjunction with the present disclosure should have the meanings commonly understood by those of ordinary skill in the art. Further, unless the context otherwise requires, singular terms should include plural terms, and plural terms should include singular terms. The aforementioned techniques and procedures are generally performed according to conventional methods well known in the art and as described in various general and more specific references cited and discussed throughout this specification. The nomenclature and laboratory procedures and techniques used in conjunction with analytical chemistry, synthetic organic chemistry, and medical and pharmaceutical chemistry as described herein are those well known and commonly used in the art.

[0020] All patents, published patent applications, and non-patent publications mentioned in this specification are indicative of the technical level of those skilled in the art to which the present disclosure pertains. All patents, published patent applications, and non-patent publications cited in any part of this application are expressly incorporated herein by reference in their entirety, as if each individual patent or publication was specifically and individually indicated to be incorporated by reference to the extent.

[0021] In accordance with the present disclosure, all compositions, devices, kits and / or methods disclosed herein can be prepared and performed without undue experimentation. Although compositions, devices, kits and / or methods have been described according to specific embodiments, it is obvious to those skilled in the art that changes can be applied to the compositions, devices, kits and / or methods described herein and the steps or step sequences of the methods without departing from the concept, spirit and scope of the present disclosure. All such similar substitutions and modifications apparent to those skilled in the art are considered to be within the spirit, scope and concept of the present disclosure as defined by the appended claims.

[0022] As utilized in accordance with this disclosure, unless otherwise indicated, the following terms shall be understood to have the following meanings:

[0023] When used in conjunction with the term "comprising" in the claims and / or the specification, the term "a" or "an" may mean "one", but it is also consistent with the meaning of "one or more", "at least one", and "one or more than one". Therefore, unless the context clearly indicates otherwise, the terms "a", "an", and "the" include plural referents. Thus, for example, a reference to a "compound" may refer to one or more compounds, two or more compounds, three or more compounds, four or more compounds, or a greater number of compounds. The term "multiple" means "two or more".

[0024] The use of the term "at least one" should be understood to include one and any number more than one, including but not limited to 2, 3, 4, 5, 10, 15, 20, 30, 40, 50, 100, etc. The term "at least one" can extend up to 100 or 1000 or more, depending on the term connected thereto; in addition, the number of 100 / 1000 is not considered limiting, as higher limits may also produce satisfactory results. In addition, the use of the term "at least one of X, Y, and Z" should be understood to include X alone, Y alone, and Z alone, as well as any combination of X, Y, and Z.

[0025] The use of ordinal numerical terms (i.e., "first," "second," "third," "fourth," etc.) is solely for the purpose of distinguishing between two or more items and is not intended to imply, for example, any order or sequence or importance of one item over another or any added order, unless expressly stated otherwise.

[0026] The use of the term "or" in the claims is intended to mean an inclusive "and / or", unless explicitly stated to refer to only alternatives, or unless the alternatives are mutually exclusive. For example, any of the following satisfies the condition "A or B": A is true (or exists) and B is false (or does not exist), A is false (or does not exist) and B is true (or exists), and both A and B are true (or exist).

[0027] As used herein, any reference to "one embodiment," "an embodiment," "some embodiments," "one example," "for example," or "an example" means that a particular element, feature, structure, or characteristic described in conjunction with the embodiment is included in at least one embodiment. For example, the phrases "in some embodiments" or "an example" appearing in various places in the specification do not necessarily all refer to the same embodiment. Further, all references to one or more embodiments or examples are to be interpreted as non-limiting to the claims.

[0028] Throughout this application, the term "about" is used to indicate that a value includes variations in the inherent errors for the composition / instrument / device, the method used to determine the value, or variations that exist in the subject of study. For example, but not as a limitation, when the term "about" is utilized, a specified value may vary from the specified value by plus or minus 20 percent, or 15 percent, or 12 percent, or 11 percent, or 10 percent, or 9 percent, or 8 percent, or 7 percent, or 6 percent, or 5 percent, or 4 percent, or 3 percent, or 2 percent, or 1 percent, as such variations are appropriate for performing the disclosed methods and as understood by one of ordinary skill in the art.

[0029] The term "antibody" is used in the broadest sense herein and refers to, for example, intact monoclonal and polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), antibody fragments and conjugates thereof (e.g., but not limited to, Fab, Fab', F(ab')2, Fv, scFv, Fd, bispecific antibodies, single-chain antibodies, and other antibody fragments and conjugates thereof that exhibit the desired biological activity of binding to an analyte, which fragments are at least partially retained in the intact antibody variable region), antibody replacement proteins or peptides (i.e., engineered binding proteins / peptides), and combinations or derivatives thereof. Antibodies may be of any type or class (e.g., IgG, IgE, IgM, IgD, and IgA) or subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2).

[0030] Biomarker: The term "biomarker" or "biological marker" as used herein, consistent with its use in the art, refers to an entity whose presence, level or form is associated with a particular biological event or state of interest, and is therefore considered a "marker" for that event or state. To name just a few examples, in some embodiments, a biomarker may be or include a marker for a particular disease state, or a marker for the likelihood that a particular disease, lesion or condition may develop, occur or recur. In some embodiments, a biomarker may be or include a marker for a particular disease or treatment outcome or its likelihood. Therefore, for a biological event or state of interest, in some embodiments, a biomarker is predictive, in some embodiments, a biomarker is prognostic, and in some embodiments, a biomarker is diagnostic. In some embodiments, a biomarker is a possible biomarker for a biological event or state of interest. A biomarker may be an entity of any chemical class. For example, in some embodiments, a biomarker may be or include a nucleic acid, a polypeptide, a small molecule, or a combination thereof. In some embodiments, a biomarker is a cell surface marker. In some embodiments, a biomarker is intracellular. In some embodiments, the biomarker is found in a specific tissue (e.g., lung tissue). In some embodiments, the biomarker is found extracellularly (e.g., secreted or otherwise produced or present extracellularly, such as in body fluids, such as blood, urine, tears, saliva, cerebrospinal fluid, etc.).

[0031] As described herein, in some embodiments, biomarkers are IPF biomarkers. "IPF biomarkers" as used herein refer to biomarkers of idiopathic pulmonary fibrosis (IPF). In some embodiments, one or more IPF biomarkers include tissue inhibitor of metalloproteinases 1 (TIMP1), hyaluronic acid (HA) and type III procollagen N-terminal propeptide (PIIINP), or a combination thereof. In some embodiments, IPF biomarkers include gene products associated with specifically described biomarkers. For example, according to the context, "TIMP1" refers to nucleotides encoding TIMP1 or its features or functional fragments, and TIMP1 protein or its features or functional fragments.

[0032] Characteristic fragment: The term "characteristic fragment" refers to a fragment of a biomarker (e.g., an IPF biomarker) that is sufficient to identify the biomarker from which the fragment is derived. For example, in some embodiments, a "characteristic fragment" of a biomarker is a fragment comprising an amino acid sequence or a set of amino acid sequences that together allow the biomarker from which the fragment is derived to be distinguished from other possible biomarkers, proteins, or polypeptides. In some embodiments, the characteristic fragment includes at least 10, at least 20, at least 30, at least 40, or at least 50 amino acids. In some embodiments, a characteristic fragment refers to a biomarker fragment that has at least 90%, at least 95%, or at least 99% sequence identity with the biomarker from which the characteristic fragment is derived.

[0033] Gene product or expression product: As used herein, the term "gene product" generally refers to RNA transcribed from a gene (before and / or after processing) or a polypeptide encoded by RNA transcribed from a gene (before and / or after modification).

[0034] Hybridization: The term "hybridization" refers to the physical property of a single-stranded nucleic acid molecule (e.g., DNA or RNA) annealing to a complementary nucleic acid molecule. Hybridization can generally be evaluated in a variety of environments, including in the case of a single study of interacting nucleic acid molecules, or in the context of a more complex system (e.g., when covalently or otherwise associated with a carrier entity and / or in a biological system or cell). In some embodiments, hybridization can be detected by hybridization techniques, such as techniques selected from in situ hybridization (ISH), microarrays, Northern blotting, and Southern blotting. In some embodiments, hybridization refers to 100% annealing between a single-stranded nucleic acid molecule and a complementary nucleic acid molecule. In some embodiments, annealing is less than 100% (e.g., at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70% of the single-stranded nucleic acid molecules anneal to complementary nucleic acid molecules). Hybridization techniques and methods for evaluating hybridization are well known in the art. See, for example, Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Press, Plainview, NY. Those skilled in the art understand how to assess and adjust the stringency of hybridization conditions so that sequences with at least the desired level of complementarity will stably hybridize, while those with lower levels of complementarity will not. For examples of hybridization conditions and parameters, see, e.g., Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Press, Plainview, NY; Ausubel, FM et al., 1994, Current Protocols in Molecular Biology. John Wiley & Sons, Secaucus, NJ.

[0035] Detection agent: As used herein, the term "detection agent" refers to any element, molecule, functional group, compound, fragment or portion that can be detected. In some embodiments, the detection agent is provided or utilized alone. In some embodiments, the detection agent is provided and / or utilized in conjunction with another agent (e.g., bound to another agent). Examples of detection agents include, but are not limited to, various ligands, radionuclides (e.g., 3 H. 14 C. 18 F. 19 F. 32 p. 35 S. 135 I. 125 I. 123I. 64 Cu, 187 Re, 111 In, 90 Y. 99m Tc, 177 Lu, 89 Zr, etc.), fluorescent dyes, chemiluminescent agents (e.g., such as acridinium esters, stabilized dioxetanes, etc.), bioluminescent agents, spectrally resolvable inorganic fluorescent semiconductor nanocrystals (i.e., quantum dots), metal nanoparticles (e.g., gold, silver, copper, platinum, etc.) nanoclusters, paramagnetic metal ions, enzymes, colorimetric markers (e.g., such as dyes, colloidal gold, etc.), biotin, dioxigenin, haptens, and proteins for which antisera or monoclonal antibodies are available.

[0036] Diagnostic test: As used herein, a "diagnostic test" is a step or series of steps that are performed or have been performed to obtain useful information that can be used to determine whether a patient has a disease, lesion or condition and / or to classify a disease, lesion or condition into a phenotypic category, or any category that is important for the prognosis of the disease, lesion or condition or the possible response to the treatment of the disease, lesion or condition (whether general treatment or any specific treatment). Similarly, "diagnosis" refers to providing any type of diagnostic information, including but not limited to whether a subject is likely to have or develop a disease, lesion or condition, the state, stage or characteristics of the disease, lesion or condition manifested by the subject, information related to the nature or classification of the tumor, information related to prognosis, and / or information that can be used to select an appropriate treatment or additional diagnostic test. The choice of treatment may include the selection of a specific therapeutic agent or other treatment modality (e.g., surgery, radiotherapy, etc.), the choice of whether to refuse to give or deliver a therapy, the choice of a dosage regimen (e.g., the frequency or level of a single dose or more doses of a specific therapeutic agent or combination of therapeutic agents), etc. The choice of additional diagnostic tests may include more specific tests for a given disease, lesion or condition.

[0037] As used in this specification and claims, the words "comprising" (and any form of comprising, such as "comprise" and "comprises"), "having" (and any form of having, such as "have" and "has"), "including" (and any form of including, such as "includes" and "include"), or "contain" (and any form of containing, such as "contains" and "contain") are inclusive or open-ended, and do not exclude additional unrecited elements or method steps. For example, a process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherently present therein.

[0038] As used herein, the term "or a combination thereof" refers to all permutations and combinations of the items listed before the term. For example, "A, B, C, or a combination thereof" is intended to include at least one of: A, B, C, AB, AC, BC, or ABC, and if the order is important in a particular context, BA, CA, CB, CBA, BCA, ACB, BAC, or CAB. Continuing with this example, explicitly included are combinations containing repetitions of one or more items or terms, such as BB, AAA, AAB, BBC, AAABCCCC, CBBAAA, CABABB, and the like. The skilled artisan will appreciate that, unless otherwise apparent from the context, there is generally no limit to the number of items or terms in any combination.

[0039] As used herein, the term "substantially" means that the event or situation described subsequently occurs completely, or the event or situation described subsequently occurs to a great extent or degree. For example, when relevant to a particular event or situation, the term "substantially" means that the event or situation described subsequently occurs at least 80% of the time, or at least 85% of the time, at least 90% of the time, or at least 95% of the time. The term "substantially adjacent" can mean that two items are 100% adjacent to each other, or two items are closely adjacent to each other, but not 100% adjacent to each other, or a part of one of the two items is not 100% adjacent to the other item, but is closely adjacent to the other item.

[0040] As used herein, the phrase "associated with" includes both direct association of two moieties with each other and indirect association of two moieties with each other. For example, non-limiting examples of association include covalent binding of one moiety to another moiety through a direct bond or through a spacer group, non-covalent binding of one moiety to another moiety directly or with the aid of a specific binding pair member that binds to the moiety, incorporation of one moiety into another moiety, such as by dissolving one moiety in the other moiety or by synthesizing and coating one moiety onto the other moiety.

[0041] As used herein, the term "biological fluid sample" should be understood to include any liquid test sample that can be obtained from a patient and utilized in accordance with the present disclosure. Examples of biological fluid samples that can be utilized include, but are not limited to, whole blood or any portion thereof (i.e., plasma or serum), saliva, sputum, mucus, nasal fluid, nasopharyngeal fluid, anterior nasal fluid, oropharyngeal fluid, tracheal fluid, bronchoalveolar fluid, cerebrospinal fluid (CSF), intestinal fluid, peritoneal effusion, cystic fluid, sweat, interstitial fluid, tears, combinations thereof, and the like.

[0042] As used herein, the term "volume" as it relates to a liquid test sample utilized in accordance with the present disclosure generally refers to a liquid test sample volume in the range of about 0.1 μl to about 100 μl, or in the range of about 1 μl to about 75 μl, or in the range of about 2 μl to about 60 μl, or a value less than or equal to about 50 μl, etc.

[0043] The term "patient" as used herein includes humans and veterinary subjects. In certain non-limiting embodiments, the patient is a mammal. In certain other non-limiting embodiments, the patient is a human. The term "mammal" for diagnostic / therapeutic purposes refers to any animal classified as a mammal, including humans, domestic and farm animals, non-human primates, and zoo, sports or pet animals, such as dogs, horses, cats, cows, etc.

[0044] A “health care provider” or “health care decision maker” includes any individual who is authorized to diagnose or treat, or assist in the diagnosis or treatment of, a patient. In the context of identifying new drugs useful for treating lung disease, a health care provider may be an individual who is not authorized to diagnose or treat, or assist in the diagnosis or treatment of a patient.

[0045] "Point of care testing" refers to real-time diagnostic testing that can be completed within a rapid time frame, so the resulting test is performed faster than a comparable test that does not employ the system. Point of care testing can be performed quickly and on-site, such as in a doctor's office, bedside, stat laboratory, emergency room, or other such locations, particularly where rapid and accurate results are needed. The patient can be present, but the patient's presence is not required. Point of care scenarios include, but are not limited to, emergency rooms, operating rooms, hospital laboratories and other clinical laboratories, doctors' offices, on-site, or any situation where rapid and accurate results are desired.

[0046] The term "specific binding partner", as used herein specifically (but not by way of limitation) in the term "target analyte-specific binding partner", should be understood to refer to any molecule capable of specifically associating with a target analyte. For example, but not by way of limitation, the binding partner may be an antibody, a receptor, a ligand, an aptamer, a molecularly imprinted polymer (i.e., an inorganic matrix), a combination or derivative thereof, and any other molecule capable of specifically binding to a target analyte.

[0047] As used herein, the term "immunoassay" refers to an assay for determining the presence of a diagnostic biomarker in a biological sample by reacting the sample with an antibody (or fragment thereof) that specifically binds to the diagnostic biomarker, wherein the reaction is carried out for a period of time under conditions that allow the formation of an immune complex between the antibody (or fragment thereof) and the diagnostic biomarker. This immune complex is then quantitatively determined.

[0048] In certain specific (but non-limiting) embodiments, the immunoassay can use a second antibody that is labeled and binds to the first antibody to detect an immobilized complex between a serum marker and a serum marker binding antibody. Alternatively, the first version is characterized by a sandwich format in which the second antibody also binds to the serum marker. In the sandwich immunoassay procedure, the serum marker binding antibody can be a capture antibody attached to an insoluble substance, and the second antibody can be a labeled antibody. The above sandwich immunoassay procedure can be used with the antibodies described below.

[0049] In other specific (but non-limiting) embodiments, the immunoassay can use a detection molecule (i.e., a second reagent) that can bind to the serum marker binding antibody and can also be detected when bound to the immune complex to detect the complex between the serum marker and the serum marker binding antibody. For example (but not by way of limitation), the second reagent can include a label attached to a receptor, a ligand, or even another copy of the serum marker.

[0050] Turning now to the specific non-limiting embodiments of the present disclosure, the embodiments of the present disclosure include the individual biomarkers of IPF, and the compositions / devices / measurements comprising the biomarkers, the methods of producing and using the biomarkers, the kits and the diagnostic tests associated therewith. For several reasons, identifying one or more IPF biomarkers is attractive and advantageous. First, the currently used IPF diagnostic criteria rely on radiographic images and / or surgical lung biopsies interpreted by doctors with interstitial lung disease expertise. This expertise is often only found in tertiary care centers, which may be geographically far away from patients and their attending physicians. Identifying one or more serum biomarkers that are diagnostic for IPF will help both clinicians and patients, particularly in the case where surgical lung biopsies cannot be obtained or the opportunity to contact with specialized interstitial lung disease doctors is limited. Secondly, the discovery of peripheral blood biomarkers reflecting disease activity will allow for continuous monitoring, and provide objective markers to assess therapeutic efficacy. Finally, the IPF biomarkers that provide prognostic information about the course of disease and / or mortality are valuable for clinical care and research study design. The present disclosure focuses on (but is not limited to) biomarkers present in peripheral blood because they are easily accessible, can be measured longitudinally, and have the greatest potential for clinical utility. Prior to the present disclosure, there were no validated biomarkers routinely used in the clinical care of IPF patients.

[0051] Certain non-limiting embodiments of the present disclosure relate to methods for determining the presence, severity and / or susceptibility of idiopathic pulmonary fibrosis (IPF) in an individual using a single biomarker. The method comprises the following steps: (a) obtaining a biological fluid sample from an individual; (b) incubating the biological fluid sample with an antibody that specifically binds to tissue inhibitor of metalloproteinase 1 (TIMP1) under conditions that allow the formation of an antibody-TIMP1 immune complex; (c) measuring the amount of the antibody-TIMP1 immune complex formed to obtain a measurement of TIMP1 in the sample; and (d) obtaining an IPF score using a mathematical algorithm based on the measurement of TIMP1 in the sample.

[0052] Any biological fluid sample known in the art or otherwise contemplated herein that may contain TIMP1, which can be detected by anti-TIMP1 antibodies and indicates IPF, can be utilized in accordance with the present disclosure. Examples of biological fluid samples that can be utilized include, but are not limited to, blood, serum, plasma, saliva, sputum, mucus, nasal fluid, nasopharyngeal fluid, anterior nasal fluid, oropharyngeal fluid, tracheal fluid, bronchial alveolar fluid, combinations thereof, and the like.

[0053] Anti-TIMP1 antibodies are well known in the art, are widely commercially available, and have been extensively studied. For example, but not by way of limitation, some commercial sources of anti-TIMP1 monoclonal and / or polyclonal antibodies include Abcam (Cambridge, UK), Biolegend, Inc. (San Jose, CA), Bio-Rad Laboratories, Inc. (Hercules, CA), Cell Signaling Technology, Inc. (Danvers, MA), Millipore Sigma (Burlington, MA), Santa Cruz Biotechnology, Inc. (Dallas, TX), Sino Biological US Inc. (Wayne, PA), Thermo Fisher Scientific (Waltham, MA), and many other sources. However, this list is not exhaustive, and there are many additional commercial sources of anti-TIMP1 antibodies that can be utilized in accordance with the present disclosure. Therefore, one of ordinary skill in the art will clearly and unambiguously be able to identify and select various anti-TIMP1 antibodies that can be utilized in accordance with the present disclosure, and therefore it is considered unnecessary to further describe the anti-TIMP1 antibodies or their characteristics.

[0054] Non-limiting examples of TIMP1 immunoassays, reagents and algorithms utilized therein that may be utilized in accordance with the present disclosure are described in detail in U.S. Pat. No. 7,141,380, issued Nov. 28, 2006, and U.S. Pat. No. 7,668,661, issued Feb. 23, 2010. The entire contents of each of the above patents are hereby expressly incorporated herein by reference.

[0055] In certain specific (but non-limiting) embodiments, the IPF score is used to support, predict, or replace the histological score of a lung biopsy.

[0056] In certain specific (but non-limiting) embodiments, the mathematical algorithm is a discriminant function algorithm, such as (but not limited to) a linear discriminant function algorithm.

[0057] In certain specific (but non-limiting) embodiments, the IPF score is at least one factor in determining an individual's treatment strategy.

[0058] In certain specific (but non-limiting) embodiments, the IPF score is at least one factor used to monitor the efficacy of a treatment strategy implemented for an individual.

[0059] In certain specific (but non-limiting) embodiments, the IPF score is at least one factor used to determine whether an individual should undergo a lung biopsy.

[0060] In certain specific (but non-limiting) embodiments, the IPF score is at least one factor used to assess the extent of IPF in an individual.

[0061] Certain non-limiting embodiments of the present disclosure relate to methods for determining the presence, severity and / or susceptibility of idiopathic pulmonary fibrosis (IPF) in an individual using two biomarkers. The method comprises the following steps: (a) obtaining a biological fluid sample from an individual or a patient; (b) selecting at least two diagnostic markers of the dynamic process of extracellular matrix synthesis and / or extracellular matrix degradation from the sample, wherein the at least two diagnostic markers are selected from tissue inhibitor of metalloproteinases 1 (TIMP1), hyaluronic acid (HA) and type III procollagen N-terminal propeptide (PIIINP); (c) measuring the amount of each of the at least two diagnostic markers in the sample to obtain a measured value of each of the at least two diagnostic markers; and (d) combining the measured values ​​of the at least two diagnostic markers using a mathematical algorithm to obtain an IPF score.

[0062] In certain specific (but non-limiting) embodiments, the at least two diagnostic markers are TIMP1 and HA.

[0063] In certain specific (but non-limiting) embodiments, the at least two diagnostic markers are TIMP1 and PIIINP.

[0064] In certain specific (but non-limiting) embodiments, at least two diagnostic markers include TIMP1, HA and PIIINP, and wherein step (d) is further defined as combining the measured values ​​of the three diagnostic markers using a mathematical algorithm to obtain an IPF score. In some embodiments, TIMP1 and PIIINP (or P3NP) are characterized as human.

[0065] HA binding proteins and / or anti-HA antibodies are well known in the art, widely commercially available, and have been extensively studied. For example, but not by way of limitation, some commercial sources of anti-HA monoclonal and / or polyclonal antibodies include Abbexa Ltd (Houston, TX), Bio-Rad Laboratories, Inc. (Hercules, CA), Biorbyt Ltd. (St. Louis, MO), Creative Diagnostics (Shirley, NY), GeneTex, Inc. (Irvine, CA), LifeSpan BioSciences (Seattle, WA), MyBioSource, Inc. (San Diego, CA), US Biological LifeSciences (Salem, MA), and many other sources. However, this list is not exhaustive, and there are many additional commercial sources of anti-HA antibodies that can be utilized in accordance with the present disclosure. Therefore, one of ordinary skill in the art will clearly and unambiguously be able to identify and select a variety of anti-HA antibodies that can be utilized in accordance with the present disclosure, and therefore, it is deemed unnecessary to further describe the anti-HA antibodies or their characteristics.

[0066] Anti-PIIINP antibodies are well known in the art, widely commercially available, and have been extensively studied. For example, but not by way of limitation, some commercial sources of anti-PIIINP monoclonal and / or polyclonal antibodies include Abbexa Ltd. (Houston, TX), Abcam (Cambridge, UK), Abnova Corporation (Walnut, CA), Antibodies-Online Inc. (Limerick, PA), Cedarlane (Burlington, Ontario), Creative Diagnostics (Shirley, NY), Millipore Sigma (Burlington, MA), MyBioSource, Inc. (San Diego, CA), Sino Biological US Inc. (Wayne, PA), and many other sources. However, this list is not exhaustive, and there are many additional commercial sources of anti-PIIINP antibodies that can be utilized in accordance with the present disclosure. Therefore, one of ordinary skill in the art will clearly and unambiguously be able to identify and select various anti-PIIINP antibodies that can be utilized in accordance with the present disclosure, and therefore it is considered unnecessary to further describe the anti-PIIINP antibodies or their characteristics.

[0067] Non-limiting examples of TIMP1, HA and PIIINP immunoassays, reagents used therein (including antibodies used therein) and algorithms that can be used in accordance with the present disclosure are described in detail in U.S. Pat. No. 7,141,380, issued on November 28, 2006, U.S. Pat. No. 7,668,661, issued on February 23, 2010, and U.S. Pat. No. 7,541,149, issued on June 2, 2009. The entire contents of each of the above patents are hereby expressly incorporated herein by reference. In some embodiments, suitable biomarkers used herein include polypeptides having the amino acid sequence shown in (UniProt Accession No. P01033), for example:

[0068] MAPFEPLASGILLLLWLIAPSRACTCVPPHPQTAFCNSDLVIRAKFVGTPEVNQTTLYQRYEIKMTKMYKGFQALGDAADIRFVYTPAMESVCGYFHRSHNRSEEFLIAGKLQDGLLHITTCSFVAPWNSLSLAQRRGFTKTYTVGCEECTVFPCLSIPCKLQSGTHCLWTDQLLQGSEKGFQSRHLACLPREPGLCTWQSLRSQIA (SEQ ID NO: 1), or a fragment or variant thereof, such as a variant having at least 95%, at least 97%, or at least 99% sequence identity with the biomarker sequence. In some embodiments, suitable biomarkers for use herein include polypeptides having the amino acid sequence shown in (UniProt Accession No. P02461 or P02461.1), such as:

[0069] MMSFVQKGSWLLLALLHPTllLAQQEAVEGGCSLGQSYADRDVWKPEPCQICVCDSGSVLCDDIICDD

[0070]

[0071] In certain specific (but non-limiting) embodiments, the IPF score is used to support, predict, or replace the histological score of a lung biopsy.

[0072] In certain specific (but non-limiting) embodiments, the mathematical algorithm is a discriminant function algorithm, such as (but not limited to) a linear discriminant function algorithm.

[0073] In certain specific (but non-limiting) embodiments, the IPF score is at least one factor in determining an individual's treatment strategy.

[0074] In certain specific (but non-limiting) embodiments, the IPF score is at least one factor used to monitor the efficacy of a treatment strategy implemented for an individual.

[0075] In certain specific (but non-limiting) embodiments, the IPF score is at least one factor used to determine whether an individual should undergo a lung biopsy.

[0076] In certain specific (but non-limiting) embodiments, the IPF score is at least one factor used to assess the extent of IPF in an individual.

[0077] The current reference standard for assessing lung fibrosis is a lung biopsy. In a biopsy, a random sample of tissue is removed from the lung and cut into thin slices that are examined by a specialist using a microscope.

[0078] There are many problems associated with lung biopsies, including the following sources of uncertainty: the distribution of fibrosis in the lung (when there is aggregated fibrosis, the needle may touch areas of the lung that are not affected by fibrosis), sample preparation failures (e.g., insufficient tissue material), and pathologist subjectivity. Further, the fibrotic state of the lung is often described using a score, and there are many different and potentially incompatible scoring systems (e.g., the CRP scoring system). For example, two independent pathologists may have to score the same biopsy sample from the same patient at two different time points using two different scoring systems.

[0079] The present disclosure facilitates point-of-care or remote diagnosis of IPF and assists healthcare providers in monitoring the status or progression of IPF at two or more time points.Importantly, the present disclosure provides healthcare decision makers with an alternative to lung biopsy, which may be inaccurate and risky.

[0080] The present disclosure adopts a computer-implementable algorithmic method, which utilizes the value of one or more IPF-related markers. The predicted value of the present disclosure has been verified in the clinical research of monitoring IPF status or progress. These clinical trials have verified the present disclosure on a horizontal basis, wherein analyzed at discrete time points, and have verified the present disclosure longitudinally, wherein analyzed at two or more time points.

[0081] Therefore, the present disclosure can be used to: (a) measure the dynamic process of extracellular matrix synthesis (fibrogenesis) and extracellular matrix degradation (fibrinolysis); and (b) obtain results reflecting the degree and dynamic changes of fibrosis occurring in lung tissue by predicting IPF histological scores.

[0082] The present disclosure is particularly useful in assisting diagnosis and treatment of patients for whom lung biopsy risk may be high. Such patients may suffer from coagulopathy, may be averse to undergoing biopsy, or may not be able to obtain expert histopathology. In addition, healthcare decision makers may use the present disclosure to assess IPF. In addition, the present disclosure is particularly useful in situations where fibrosis may be unevenly distributed and sampling errors pose a serious problem.

[0083] In one non-limiting embodiment, the present disclosure provides a method for assisting in diagnosing a patient's IPF status or progression by determining a predictor value at each time point at one or more time points, wherein a healthcare decision maker uses a comparison of the predictor value and a comparison data set at one or more time points to ascertain the patient's IPF status or progression, and wherein the patient's predictor value is calculated by inputting data for one or more blood markers (e.g., one or more plasma or serum markers) and optionally one or more supplemental markers into a linear or nonlinear function algorithm derived by correlating reference IPF histopathology and blood markers (e.g., plasma or serum marker data).

[0084] The comparison data set can include any data of any qualitative or quantitative index reflecting histopathological condition. In a non-limiting embodiment, the comparison data set can include one or more numerical values ​​or numerical ranges relevant to histopathological condition. For example, the comparison data set can include various integer sets (for example, integer 0 to 5), wherein the different groupings of these six integers are relevant to different IPF disease states (for example, 0-1 can be relevant to mild disease states, 2-3 is relevant to moderate disease states, and 4-5 can be relevant to severe disease states). Therefore, the comparison data set can be relevant to established lung biopsy scoring system (for example, clinical radiophysiology (CRP) scoring system).

[0085] In a specific (but non-limiting) embodiment, the blood marker is a serum marker selected from one or more of the following: tissue inhibitor of metalloproteinases 1 (TIMP1), N-terminal type III procollagen propeptide (PIIINP) and hyaluronic acid. Supplementary markers include, but are not limited to, patient weight, sex, age and transaminase levels.

[0086] In another non-limiting embodiment of the present disclosure, a linear or nonlinear function algorithm is derived by associating reference IPF histopathology and blood markers (e.g., plasma and serum markers) data using discriminant function analysis or nonparametric regression analysis. Reference IPF histopathology and blood marker data (e.g., plasma and serum marker data) may include data indicating fibrosis or fibrolysis, elevated IPF serum markers, or other IPF clinical symptoms.

[0087] In one non-limiting embodiment, reference to IPF histopathology and blood marker data (e.g., blood plasma and serum marker data) is based on the data relevant to one or more subjects except diagnosing the patient. In another non-limiting embodiment, reference to IPF histopathology and blood marker data (e.g., blood plasma and serum marker data) is based on the data previously obtained from diagnosing the patient, and optionally also based on the data obtained from one or more other subjects.

[0088] In one non-limiting embodiment, the linear or nonlinear function algorithm is derived by correlating reference IPF histopathology and blood marker data (e.g., plasma and serum marker data), wherein the linear or nonlinear function algorithm is derived by: (a) compiling a data set comprising blood marker data (e.g., plasma or serum marker data) and histopathology data for a first group of subjects; (b) deriving the linear or nonlinear function algorithm from the compiled data set by applying an analytical method; (c) calculating a validation biopsy score value for a second group of subjects by inputting data comprising blood marker data (e.g., plasma or serum marker data) values ​​for a second group of subjects into the algorithm derived in step (b); and (d) comparing the validation biopsy score value calculated in step (c) with the IPF histopathology score for the second group of subjects. and (e) if the validation biopsy score determined in step (c) does not correlate with the IPF histopathology score of the second group of subjects within a clinically acceptable tolerance level, performing the following operations (i)-(iii) until such tolerance is met: (i) modifying the algorithm on one or more bases, the bases comprising (1) modifying the data set of the first group of subjects, and (2) modifying or changing the analytical method; (ii) calculating the validation biopsy score value for the second group of subjects by inputting data comprising blood marker data (e.g., plasma or serum marker data) values ​​for the second group of subjects into the modified algorithm; (iii) evaluating whether the validation biopsy score value calculated using the modified algorithm correlates with the lung histopathology score for the second group of subjects within a clinically acceptable tolerance level.

[0089] Analytical methods may include statistical techniques, including discriminant function analysis and nonparametric regression analysis, as well as techniques such as classification trees or neural networks.

[0090] In another non-limiting embodiment, the present disclosure provides a data structure stored in a computer-readable medium, which can be read by a microprocessor and includes at least one code that uniquely identifies a linear or nonlinear function algorithm derived in the manner described herein.

[0091] In another non-limiting embodiment, the present disclosure provides a diagnostic kit comprising: (a) a data structure stored in a computer-readable medium, which can be read by a microprocessor and includes at least one code that uniquely identifies a linear or nonlinear function algorithm derived in the manner described herein; and (b) one or more immunoassays for detecting and determining a patient's serum marker value.

[0092] In another non-limiting embodiment, the present disclosure provides computer-implemented methods and systems for determining whether a composition is useful for treating IPF, comprising evaluating data useful for diagnosing the status or progression of IPF in a patient treated with the composition, wherein: (a) a diagnosis is made by a healthcare provider by algorithmically determining a predictor variable value at each time point at one or more time points; (b) the healthcare provider uses a comparison of the predictor variable values ​​and a comparison data set at one or more time points to ascertain the status or progression of IPF in the patient; and (c) the predictor variable value for the patient is calculated by inputting one or more blood markers (e.g., plasma or serum markers) into a linear or nonlinear function algorithm derived by correlating reference IPF histopathology and blood marker data (e.g., plasma or serum marker data).

[0093] Healthcare providers may also use the above-described methods, systems, and kits of the present disclosure to: (1) determine treatment regimens for patients susceptible to or suffering from IPF; and (2) design clinical procedures that can be used to monitor IPF status or progression in one or more patients.

[0094] "Discriminant function analysis" is a technique for determining variables that distinguish between two or more naturally occurring mutually exclusive groups. The underlying basic idea of ​​discriminant function analysis is to determine whether the groups differ on a set of predictor variables that may or may not be independent of each other, and then use these variables to predict group membership (e.g., new cases).

[0095] Discriminant function analysis starts with a categorical (two or more mutually exclusive levels) outcome variable. The model assumes that these levels can be distinguished by a set of predictor variables, which, like ANOVA (Analysis of Variance), can be continuous or categorical, and, like ANOVA, assumes that its underlying discriminant function is linear. Discriminant analysis does not "partition the variation." It finds canonical correlations among a set of predictor variables, and uses these correlations to construct a characteristic function that explains the total percentage of variation in all predictor variables at all levels of the outcome variable.

[0096] The output of the analysis is a set of linear discriminant functions (eigenfunctions) that use combinations of predictor variables to generate "discriminant scores" independent of the level of the outcome variable. The percentage of total variation is displayed for each function. In addition, for each eigenfunction, a set of Fisher discriminant functions was developed that produce a discriminant score based on the combination of predictor variables within each level of the outcome variable.

[0097] Typically, several variables are included in the study to understand which variable(s) contribute to the distinction between groups. In this case, a total variance and covariance matrix is ​​generated. Similarly, a combined within-group variance and covariance matrix can be generated. The two matrices are compared by a multivariate F test to determine if there are any significant differences between the groups (for all variables). This process is the same as multivariate analysis of variance or MANOVA. As in MANOVA, a multivariate test can be performed first, and if statistically significant, then proceed to understand which variables have significantly different means between groups.

[0098] For a set of observations containing one or more quantitative variables and categorical variables that define the groups of observations, a discriminant procedure develops a discriminant criterion to classify each observation into one of the groups. In order to understand how well the discriminant criterion "performs", it is necessary to classify different cases (a priori), i.e., cases that were not used to estimate the discriminant criterion. Only the classification of new cases allows the predictive validity of the discriminant criterion to be assessed.

[0099] To validate the derived criterion, the classification can be applied to other data sets. The data set used to derive the discriminant criterion is called a training or calibration data set or a patient training cohort. The data set used to verify the performance of the discriminant criterion is called a validation data set or validation cohort.

[0100] The discriminant criteria (one or more functions or algorithms) determine the measure of generalized square distances. These distances are based on the combined covariance matrix. The Mahalanobis distance or Euclidean distance can be used to determine proximity. These distances can be used to identify groupings of outcome levels and thereby determine possible reductions in the variable levels.

[0101] The "pooled covariance matrix" is a numeric matrix formed by adding together the components of the covariance matrix for each subpopulation in the analysis.

[0102] A "predictor variable" is any variable that can be applied to a function to generate a dependent variable or a response variable or a "predictor variable value". In one non-limiting embodiment of the present disclosure, a predictor variable value can be a discriminant score determined by performing a discriminant function analysis on two or more patient blood markers (e.g., plasma or serum markers). For example, a linear model specifies a (linear) relationship between a dependent variable (or response variable) Y and a set of predictor variables X, such that

[0103] Y=b0+b1X1+b2X2+...+b k X k

[0104] In this equation, b0 is the regression coefficient of the intercept, and b i The values ​​are the regression coefficients (for variables 1 to k) calculated from the data.

[0105] Classification trees are used to predict the membership of cases or objects in the categories of a categorical dependent variable based on their measured values ​​on one or more predictor variables. Classification tree analysis is one of the main techniques used in so-called data mining. The goal of classification trees is to predict or explain the response to a categorical dependent variable, and as such, the techniques available to them have much in common with those used in more traditional methods of discriminant analysis, cluster analysis, nonparametric statistics, and nonlinear estimation.

[0106] The flexibility of classification trees makes them a very attractive analytical option, but this is not to suggest that classification trees should be used to the exclusion of more traditional methods. In fact, traditional methods can be preferred when the often more stringent theoretical and distributional assumptions of the more traditional methods are met. But as an exploratory technique, or as a last resort when traditional methods fail, many researchers believe that classification trees excel. Classification trees are widely used in a variety of application areas, such as medicine (diagnosis), computer science (data structures), botany (classification), and psychology (decision theory). Classification trees are easy to display graphically, which helps make them easier to interpret than would be possible with a strict numerical interpretation alone.

[0107] "Neural networks" are analytical techniques that imitate the learning processes in (hypothetical) cognitive systems and the neural functions of the brain and are able to predict new observations (of a specific variable) based on other observations (of the same or other variables) after performing a process called learning from existing data. Neural networks are one of the data mining techniques. The first step is to design a specific network architecture (comprising a specific number of "layers", each consisting of a certain number of "neurons"). The size and structure of the network need to match the nature of the phenomenon being studied (e.g. formal complexity). Since the latter is obviously not very well known at this early stage, this task is not easy and often involves many "trials and errors".

[0108] The neural network is then subjected to a "training" process. During this phase, the computer memory acts as neurons and an iterative process is applied to the number of inputs (variables) to adjust the weights of the network in order to best predict the sample data on which the "training" is performed. After the phase of learning from the existing data set, the new network is ready and can then be used to generate predictions.

[0109] In one non-limiting embodiment of the present disclosure, a neural network may include the memory of one or more personal or mainframe computers or computerized point-of-care devices.

[0110] Although the present disclosure will be described in the general context of computer executable instructions of computer programs running on personal computers, those skilled in the art will recognize that the present disclosure can also be implemented in combination with other program modules. Typically, program modules include routines, programs, components and data structures that perform specific tasks or implement specific abstract data types. In addition, those skilled in the art will appreciate that the present disclosure can be implemented together with other computer system configurations, including handheld devices, multiprocessor systems, microprocessor-based or programmable consumer electronics, minicomputers, mainframe computers, etc. The present disclosure can also be implemented in a distributed computing environment, where tasks are performed by remote processing devices connected through a communication network. In a distributed computing environment, program modules can be located in both local and remote memory storage devices.

[0111] The diagnostic system of the present disclosure may include a handheld device useful in point-of-care applications, or may be a system remotely operated from the patient care site. In either case, the system may include supporting software programmed in any useful language to implement the diagnostic method of the present disclosure according to the algorithms or other analytical techniques described herein.

[0112] The “validation cohort marker score value” refers to the numerical score derived from the linear combination of the discriminant weights obtained from the training cohort and the marker value for each patient in the validation cohort.

[0113] A "patient diagnostic marker cutoff value" refers to the value of a marker or combination of markers that achieves a predetermined sensitivity or specificity.

[0114] "Negative predictive value" ("NPV") refers to the probability of not having the disease if the value of a marker (or a set of marker values) is not above a defined cutoff value.

[0115] "Positive predictive value" ("PPV") refers to the probability of having a disease if the value of a marker (or a set of marker values) is above a defined cutoff value.

[0116] A "receiver operating characteristic curve" ("ROC") refers to a graphical representation of the functional relationship between the distribution of sensitivity of a marker and the value of (1 - specificity) in a patient cohort and a non-patient cohort.

[0117] The "area under the curve" ("AUC") is a number that represents the area under the receiver operating characteristic curve. The closer this number is to 1, the better the marker's value is at discriminating between the diseased and non-disease cohorts.

[0118] The "McNemar's chi-square test" ("McNemar's χ2 test") is a statistical test used to determine whether two related proportions (proportions with a common numerator but different denominators) are significantly different from each other.

[0119] "Nonparametric regression analysis" is a set of statistical techniques that allow straight lines to be fitted to bivariate data, making few assumptions about the distribution of each variable or the estimated error of each variable. Non-limiting examples include Theil location estimator, Passing-Bablok regression, and Deming regression.

[0120] A "cutoff value" is a numerical value for a marker (or set of markers) that defines a certain sensitivity or specificity.

[0121] Reagent test kit

[0122] The present disclosure also provides a kit, which includes one or more anti-IPF biomarker agents and instructions for use (e.g., treatment, prevention or diagnostic purposes). In some embodiments, the kit is used for in vitro diagnostic determination to diagnose IPF. In some embodiments, the one or more anti-IPF biomarker agents include antibody agents. In some embodiments, the one or more antibody agents are labeled with a detectable portion. In some embodiments, the kit further includes a detection agent (e.g., one or more acridinium ester molecules). In some embodiments, the one or more antibody agents are labeled with one or more acridinium ester molecules. In some embodiments, the kit also includes one or more second antibody agents that specifically bind to one or more of the anti-IPF biomarker antibody agents.

[0123] In some embodiments, the one or more anti-IPF biomarker agents include nucleic acid probes. In some embodiments, at least a portion of each nucleic acid probe is hybridized with one or more portions of nucleotides encoding IPF biomarkers (e.g., tissue inhibitor of metalloproteinases 1 (TIMP1), hyaluronic acid (HA) and type III procollagen N-terminal propeptide (PIIINP) or a combination thereof). The nucleotides encoding IPF biomarkers can be DNA (e.g., cDNA) or RNA (e.g., mRNA). In some embodiments, the nucleic acid probe is labeled with one or more detection agents (e.g., wherein the detection agent indicates the presence of nucleotides encoding IPF biomarkers).

[0124] In some embodiments, the kit further comprises one or more control samples. In some embodiments, the control sample comprises one or more IPF biomarker standards. In some embodiments, IPF biomarker standards include recombinant IPF biomarkers (e.g., tissue inhibitor of metalloproteinases 1 (TIMP1), hyaluronic acid (HA) and type III procollagen N-terminal propeptide (PIIINP) or a combination thereof). In some embodiments, IPF biomarker standards include synthetic IPF biomarkers (e.g., tissue inhibitor of metalloproteinases 1 (TIMP1), hyaluronic acid (HA) and type III procollagen N-terminal propeptide (PIIINP) or a combination thereof) nucleic acids.

[0125] In addition to the foregoing, the kit may include other ingredients, such as solvents or buffers, stabilizers or preservatives, and / or medicaments for treating illnesses described herein or pathological changes. Alternatively, other ingredients may be included in the kit, but its composition or container is different from the anti-IPF biomarker agent. In such embodiments, the kit may include instructions for mixing anti-IPF biomarker agents and other ingredients, or instructions for using anti-IPF biomarkers and other ingredients together.

[0126] In certain embodiments, kits for use in accordance with the present disclosure may include a reference or control sample, instructions for processing the sample, instructions for performing a test on the sample, instructions for interpreting the results, buffers, and / or other reagents necessary to perform the test.

[0127] The disclosure also provides the following understanding, that is, some single IPF biomarker can contribute to the detection and / or diagnosis of IPF. The disclosure further provides the following insight, that is, the specific combination of IPF biomarkers is particularly suitable for detecting and / or diagnosing IPF. Therefore, methods described herein, compositions and kits can be used for following determinations, to assess IPF risk, assess whether the subject should receive further lung examinations and / or based on the detection or measurement of the IPF biomarkers in the sample (e.g., biological sample obtained from the subject) to diagnose IPF.

[0128] Method and kit provided herein can detect IPF in sample, and its sensitivity and specificity make test result reliable enough to have medical feasibility.Method and kit for detecting and / or diagnosing IPF in subject described herein detect IPF with sensitivity greater than 75%, greater than 80%, greater than 85%, greater than 90%, greater than 95%, greater than 96%, greater than 97%, greater than 98%, greater than 99% or about 100%.In some embodiments, method and kit provided herein can detect IPF with sensitivity between about 70%-100%, between about 80%-100% or between about 90%-100%.In some embodiments, method and kit provided herein can detect IPF with sensitivity and specificity between about 50%-100%, between about 60%-100%, between about 70%-100%, between about 80%-100% or between about 90%-100%.

[0129] Composition

[0130] Compositions are also provided herein. In some embodiments, the composition comprises one or more IPF biomarkers and one or more anti-IPF biomarker agents. In some embodiments, one or more IPF biomarkers comprise tissue inhibitor of metalloproteinase 1 (TIMP1), hyaluronic acid (HA) and type III procollagen N-terminal propeptide (PIIINP) or a combination thereof, and one or more anti-IPF biomarker agents comprise anti-TIMP1 agents, anti-HA agents, anti-PIIINP agents or a combination thereof.

[0131] In some embodiments, the composition includes a combination (e.g., a combination of one or more, two or more, or three IPF biomarkers and corresponding anti-IPF biomarker agents). In some embodiments, the one or more, two or more, or three IPF biomarkers are present in an amount sufficient to demonstrate the presence of IPF in the patient.

[0132] In some embodiments, the composition includes two or more IPF biomarkers and two or more anti-IPF biomarker agents. In some embodiments, two or more IPF biomarkers include tissue inhibitor of metalloproteinases 1 (TIMP1), hyaluronic acid (HA) and type III procollagen N-terminal propeptide (PIIINP) or a combination thereof, and two or more anti-IPF biomarker agents include anti-TIMP1 agents, anti-HA agents, anti-PIIINP agents or a combination thereof.

[0133] In some embodiments, the composition includes three IPF biomarkers and three or more anti-IPF biomarker agents. In some embodiments, the three IPF biomarkers include tissue inhibitor of metalloproteinase 1 (TIMP1), hyaluronic acid (HA) and type III procollagen N-terminal propeptide (PIIINP) or a combination thereof. In some embodiments, three or more anti-IPF biomarker agents include anti-TIMP1 agent, anti-HA agent, anti-PIIINP agent or a combination thereof.

[0134] Computer Systems

[0135] Method described herein can be implemented in a computer system with a processor that performs specific instructions in a computer program. In some embodiments, the computer system can be arranged to output an IPF biomarker score based on the IPF biomarker overview received and / or the level of two or more IPF biomarkers. Specifically, the computer program may include instructions that make the system select appropriate subsequent steps, including additional drugs, treatment and / or additional testing to the experimenter.

[0136] In some embodiments, computer program can be configured to make computer system can identify experimenter to carry out further test (for example lung test), identify experimenter as being at risk or suffering from IPF, and / or identify experimenter to accept medicine and use the data to calculate IPF biomarker score based on received data (for example IPF biomarker overview).System can carry out rank order to the subsequent steps identified based on IPF biomarker overview and demographic factors and / or based on the biomarker of imaging.System can adjust rank order based on the clinical response of experimenter or experimenter family member who for example suffers from or is suspected of suffering from IPF.

[0137] Figure 2 1 is a block diagram of a computer system 1100 that can be used for the operations described above, according to one embodiment. The system 1100 includes a processor 1110, a memory 1120, a storage device 1130, and an input / output device 1140. Each of the components 1110, 1120, 1130, and 1140 are interconnected using a system bus 1150. The system may include an analytical device 1160 for determining the level of one or more biomarkers of the present disclosure in a sample.

[0138] In some embodiments, the processor 1110 is capable of processing instructions for execution within the system 1100. In one embodiment, the processor 1110 is a single-threaded processor. In another embodiment, the processor 1110 is a multi-threaded processor. The processor 1110 is capable of processing instructions stored in the memory 1120 or on the storage device 1130, including instructions for receiving or sending information through the input / output device 1140.

[0139] In some embodiments, memory 1120 stores information within system 1100. In one embodiment, memory 1120 is a computer readable medium. In one embodiment, memory 1120 is a volatile memory unit. In another embodiment, memory 1120 is a non-volatile memory unit.

[0140] The storage device 1130 is capable of providing mass storage for the system 1100. In one embodiment, the storage device 1130 is a computer-readable medium.

[0141] The input / output device 1140 provides input / output operations for the system 1100. In one embodiment, the input / output device 1140 includes a keyboard and / or a pointing device. In one embodiment, the input / output device 1140 includes a display unit for displaying a graphical user interface.

[0142] The system 1100 may be used to construct a database. Figure 3 A flow chart of a method 1200 for constructing a database is shown, which is used to identify a subject for further testing (e.g., IPF testing), identify a subject as being at risk or suffering from IPF, and / or identify a subject to receive medication. Preferably, method 1200 is performed in system 1100. For example, a computer program product may include instructions that cause processor 1110 to perform the steps of method 1200 or method 1300.

[0143] Reference now Figure 3, method 1200 includes the following steps. In step 1210, receive the IPF biomarker profile of the experimenter (e.g., the level of one or more IPF biomarkers in the sample). The computer program in system 1100 may include instructions for displaying a suitable graphical user interface on input / output device 1140, and the graphical user interface may prompt the user to input level 1170 using input / output device 1140 such as a keyboard. In step 1220, calculate the IPF biomarker score from the IPF biomarker profile. As described herein, in step 1220, calculate the IPF biomarker score from (i) the IPF biomarker profile and (ii) demographic factors and / or image-based biomarkers. In step 1230, store the IPF biomarker score. System 1100 may store the IPF biomarker score in storage device 1130. Additionally or alternatively, system 1100 may provide a reading including the IPF biomarker score. The readout may also include suggested next steps for the subject and / or a confidence level associated with the IPF biomarker score.

[0144] Reference now Figure 4 , method 1300 includes the following steps. In step 1310, the level of one or more IPF biomarkers in a sample (e.g., a sample from a subject) is detected. In step 1320, an IPF biomarker profile is obtained using the level of one or more IPF biomarkers. In step 1330, an IPF biomarker score is calculated from the IPF biomarker profile. As described herein, in step 1330, an IPF biomarker score is calculated from (i) an IPF biomarker profile and (ii) demographic factors and / or image-based biomarkers. In step 1340, an IPF biomarker score is stored. System 1100 may store an IPF biomarker score in a storage device 1130. Additionally or alternatively, system 1100 may provide a reading including an IPF biomarker score. The reading may also include subsequent steps suggested to the subject and / or a confidence level associated with the IPF biomarker score.

[0145] Additionally, a non-transient computer-readable medium comprising executable instructions is also provided, which causes a processor to perform operations including the methods provided herein when the instructions are executed. For example, a non-transient computer-readable medium contains executable instructions, which causes a processor to perform operations including the methods of 1200 or 1300 described above when the instructions are executed. In some embodiments, the non-transient computer-readable medium includes a hard drive, an external hard drive, an optical disk, a CD, a DVD, and similar devices storing data. In some embodiments, the software located in the physical medium is suitable for use herein.

[0146] In some embodiments, a non-transitory computer-readable medium comprises executable instructions that, when executed, cause a processor to perform operations including a method for determining the presence, severity and / or susceptibility of idiopathic pulmonary fibrosis (IPF) in an individual, the method comprising the following steps: (a) incubating a biological fluid sample with an antibody that specifically binds to tissue inhibitor of metalloproteinase 1 (TIMP1) under conditions that allow the formation of an antibody-TIMP1 immune complex; (b) measuring the amount of the antibody-TIMP1 immune complex formed to obtain a measurement of TIMP1 in the sample; and (c) obtaining an IPF score based on the measurement of TIMP1 in the sample using a mathematical algorithm.

[0147] Exemplary numbering implementation scheme

[0148] Embodiment 1: A method for determining the presence, severity and / or susceptibility of idiopathic pulmonary fibrosis (IPF) in an individual, the method comprising the following steps: (a) obtaining a biological fluid sample from the individual; (b) incubating the biological fluid sample with an antibody that specifically binds to tissue inhibitor of metalloproteinase 1 (TIMP1) under conditions that allow the formation of an antibody-TIMP1 immune complex; (c) measuring the amount of the antibody-TIMP1 immune complex formed to obtain a measurement value of TIMP1 in the sample; and (d) obtaining an IPF score based on the measurement value of TIMP1 in the sample using a mathematical algorithm.

[0149] Embodiment 2: The method of embodiment 1, wherein the biological fluid sample is selected from the group consisting of blood, serum, plasma, saliva, sputum, mucus, nasal fluid, nasopharyngeal fluid, anterior nasal fluid, oropharyngeal fluid, tracheal fluid, bronchoalveolar fluid, and combinations thereof.

[0150] Embodiment 3: The method of embodiment 1, wherein the IPF score is used to support, predict or replace the histological score of the lung biopsy.

[0151] Embodiment 4: The method of embodiment 1, wherein the mathematical algorithm is a discriminant function algorithm.

[0152] Embodiment 5: The method of embodiment 1, wherein the discriminant function algorithm is a linear discriminant function algorithm.

[0153] Embodiment 6: The method of embodiment 1, wherein the IPF score is at least one factor in determining the individual's treatment strategy.

[0154] Embodiment 7: The method of Embodiment 1, wherein the IPF score is at least one factor used to monitor the efficacy of a treatment strategy implemented for the individual.

[0155] Embodiment 8: The method of Embodiment 1, wherein the IPF score is at least one factor used to determine whether the individual should undergo a lung biopsy.

[0156] Embodiment 9: The method of embodiment 1, wherein the IPF score is at least one factor used to assess the extent of IPF in the individual.

[0157] Embodiment 10: A method for determining the presence, severity and / or susceptibility of idiopathic pulmonary fibrosis (IPF) in an individual, the method comprising the following steps: (a) obtaining a biological fluid sample from the individual; (b) selecting at least two diagnostic markers of the dynamic process of extracellular matrix synthesis and / or extracellular matrix degradation from the sample, wherein the at least two diagnostic markers are selected from tissue inhibitor of metalloproteinase 1 (TIMP1), hyaluronic acid (HA) and type III procollagen N-terminal propeptide (PIIINP); (c) measuring the amount of each of the at least two diagnostic markers in the sample to obtain a measurement value for each of the at least two diagnostic markers; and (d) combining the measurement values ​​of the at least two diagnostic markers using a mathematical algorithm to obtain an IPF score.

[0158] Embodiment 11: The method of embodiment 10, wherein the at least two diagnostic markers are TIMP1 and HA.

[0159] Embodiment 12: The method according to embodiment 10, wherein the at least two diagnostic markers are TIMP1 and PIIINP.

[0160] Embodiment 13: The method according to embodiment 10, wherein the at least two diagnostic markers include TIMP1, HA and PIIINP, and wherein step (d) is further defined as combining the measured values ​​of the three diagnostic markers using a mathematical algorithm to obtain an IPF score.

[0161] Embodiment 14: The method according to embodiment 10, wherein the IPF score is used to support, predict or replace the histological score of the lung biopsy.

[0162] Embodiment 15: A method according to embodiment 10, wherein the mathematical algorithm is a discriminant function algorithm.

[0163] Embodiment 16: A method according to embodiment 15, wherein the discriminant function algorithm is a linear discriminant function algorithm.

[0164] Embodiment 17: The method of embodiment 16, wherein the IPF score is at least one factor in determining an individual's treatment strategy.

[0165] Embodiment 18: The method of embodiment 10, wherein the IPF score is at least one factor used to monitor the efficacy of a treatment strategy implemented for the individual.

[0166] Embodiment 19: The method of embodiment 10, wherein the IPF score is at least one factor used to determine whether the individual should undergo a lung biopsy.

[0167] Embodiment 20: The method according to embodiment 10, wherein the IPF score is at least one factor used to assess the extent of IPF in an individual.

[0168] Embodiment 21: A non-transitory computer readable medium comprising executable instructions which, when executed, cause a processor to perform operations comprising the method of any one of Embodiments 1-20.

[0169] Embodiment 22: A composition comprising:

[0170] (a) one or more IPF biomarkers, wherein the one or more IPF biomarkers include: tissue inhibitor of metalloproteinase 1 (TIMP1), hyaluronic acid (HA) and type III procollagen N-terminal propeptide (PIIINP) or a combination thereof; and (b) one or more anti-IPF biomarker agents, wherein the one or more anti-IPF biomarker agents include: anti-TIMP1 agent, anti-HA agent, anti-PIIINP agent or a combination thereof. In some embodiments, the one or more anti-IPF biomarker agents are artificial or synthetic.

[0171] Embodiment 23: A kit for detecting IPF, the kit comprising:

[0172] (a) one or more anti-IPF biomarker agents, wherein the one or more anti-IPF biomarker agents include: (i) an anti-TIMP1 agent, (ii) an anti-HA agent, (iii) an anti-PIIINP agent, (iv) a combination thereof; and

[0173] (b) Instructions for use.

[0174] Embodiment 24: A kit for detecting IPF, the kit comprising: (a) one or more anti-IPF biomarker agents, wherein the one or more anti-IPF biomarker agents include (i) anti-TIMP1 agent and anti-HA agent, (ii) anti-PIIINP agent and anti-TIMP1 agent, or (iii) anti-HA agent, anti-PIIINP agent and anti-TIMP1 agent; and (b) instructions for use.

[0175] Embodiment 25: A kit comprising: (a) one or more anti-IPF biomarker agents, wherein the one or more anti-IPF biomarker agents include an anti-TIMP1 agent, an anti-HA agent, and an anti-PIIINP agent; and (b) instructions for use.

[0176] Embodiment 26: The kit of any one of Embodiments 23-25, wherein the one or more anti-IPF biomarker agents comprise one or more antibody agents.

[0177] Embodiment 27: The kit of Embodiment 26, wherein the one or more antibody agents are labeled with a detectable moiety.

[0178] Embodiment 28: The kit of embodiments 23-27, further comprising one or more control samples.

[0179] Embodiment 29: The kit of Embodiment 28, wherein the control sample comprises one or more IPF biomarker standards.

[0180] Embodiment 30: Use of the kit according to embodiments 23-29 in an in vitro diagnostic assay for diagnosing IPF in a subject. Example

[0181] Examples are provided below. However, it should be understood that the application of the present disclosure is not limited to the specific experiments, results and laboratory procedures disclosed herein below. On the contrary, the examples are provided as one of the various embodiments only and are intended to be illustrative, not exhaustive.

[0182] The present embodiment is directed to measuring IPF biomarkers in a convenient blood sample to accurately identify (ie, aid in diagnosis) and potentially monitor IPF progression in patients.

[0183] The biomarkers tested were tissue inhibitor of metalloproteinase 1 (TIMP1), hyaluronic acid (HA), and type III procollagen N-terminal propeptide (PIIINP). These tests are immunoassays run on various automated immunoassay platforms (such as, but not limited to, and ADVIA Immunoassay Analyzer System (Siemens Healthineers, Inc.; Malvern, PA). Biomarkers can be used alone or in combination with each other and / or with other patient clinical data to accurately identify patients with IPF.

[0184] In this example, 99 patient serum samples were tested using the Siemens TIMP1, HA and PIIINP immunoassays. Of these, 53 samples were from confirmed IPF patients and 46 control patient samples consisted of 23 smokers and 23 non-smokers.

[0185] Logistic regression was used to compare biomarkers to predict the probability of IPF versus controls.

[0186] Performance results were calculated by performing a leave-10 cross-validation, where the logistic model was rebuilt five hundred times. Each time the model was built, only 89 of the 99 samples were used to build the model. This model was then used to predict the remaining 10 samples. The sensitivity and specificity derived from comparing these 10 samples to the clinical truth were averaged across all 500 simulations / iterations to give the performance of the cross-validated sensitivity and specificity.

[0187] The predictive value of TIMP1 alone for identifying IPF was excellent, with a best sensitivity of 91.7% and a specificity of 87.2%. Figure 1 The receiver operating characteristic curve (ROC) of the study group is shown in Table 1 below.

[0188] Table 1 - TIMP1 ROC

[0189]

[0190]

[0191] The predictive value of combining TIMP1 and HA with regression analysis further improved the prediction of IPF relative to controls, as shown in Table 2.

[0192] Table 2 - TIMP1 and HA ROC

[0193] Cut-off probability Sensitivity Specificity 70% 69.50% 93.70% 55% 86.60% 90.80% 50% 92.30% 90.10% 45% 95.40% 86.20% 40% 96.20% 84.00% 30% 96.20% 77.80% 20% 96.50% 60.20% 10% 98.30% 38.00% 5% 98.10% 15.10%

[0194] Therefore, this example demonstrates the use of TIMP1 alone or in combination with HA to reliably predict IPF in a logistic regression model. In a logistic regression model, the combination of TIMP1, HA and other clinical data biomarkers (such as but not limited to PIIINP) provides a distinguishing scoring system for more accurately staging and grading IPF, as well as more accurately monitoring disease progression and response to treatment.

[0195] Therefore, according to the present disclosure, compositions, devices and kits, and methods of producing and using the same, are provided, which fully satisfy the above-mentioned objects and advantages. Although the present disclosure has been described in conjunction with the above-mentioned specific drawings, experiments, results and expressions, it is obvious that many alternatives, modifications and variations are obvious to those skilled in the art. Therefore, it is intended to cover all such alternatives, modifications and variations that fall within the spirit and broad scope of the present disclosure.

Claims

1. A method for determining the presence, severity and / or susceptibility to idiopathic pulmonary fibrosis (IPF) in an individual, the method comprising the steps of: (a) obtaining a biological fluid sample from an individual; (b) incubating the biological fluid sample with an antibody that specifically binds to tissue inhibitor of metalloproteinase 1 (TIMP 1) under conditions that allow formation of an antibody-TIMP 1 immune complex; (c) measuring the amount of the antibody-TIMP 1 immune complex formed to obtain a measurement value of TIMP 1 in the sample; as well as (d) deriving an IPF score using a mathematical algorithm based on the measured value of TIMP1 in the sample.

2. The method of claim 1, wherein the biological fluid sample is selected from the group consisting of blood, serum, plasma, saliva, sputum, mucus, nasal fluid, nasopharyngeal fluid, anterior nasal fluid, oropharyngeal fluid, tracheal fluid, bronchoalveolar fluid, and combinations thereof.

3. The method of claim 1, wherein the IPF score is used to support, predict or replace the histological score of lung biopsy. The method of claim 1 , wherein the mathematical algorithm is a discriminant function algorithm. The method according to claim 1 , wherein the discriminant function algorithm is a linear discriminant function algorithm.

6. The method of claim 1, wherein the IPF score is at least one factor in determining a treatment strategy for the individual.

7. The method of claim 1, wherein the IPF score is at least one factor used to monitor the efficacy of a treatment strategy implemented for the individual.

8. The method of claim 1, wherein the IPF score is at least one factor used to determine whether the individual should undergo a lung biopsy.

9. The method of claim 1, wherein the IPF score is at least one factor used to assess the extent of IPF in the individual.

10. A method of determining the presence, severity and / or susceptibility to idiopathic pulmonary fibrosis (IPF) in an individual, the method comprising the steps of: (a) obtaining a biological fluid sample from an individual; (b) selecting from the sample at least two diagnostic markers of the dynamic process of extracellular matrix synthesis and / or extracellular matrix degradation, wherein the at least two diagnostic markers are selected from tissue inhibitor of metalloproteinase 1 (TIMP1), hyaluronic acid (HA) and type III procollagen N-terminal propeptide (PIIINP); (c) measuring the amount of each of the at least two diagnostic markers in the sample to obtain a measurement value for each of the at least two diagnostic markers; as well as (d) combining the measured values ​​of the at least two diagnostic markers using a mathematical algorithm to obtain an IPF score.

11. The method of claim 10, wherein the at least two diagnostic markers are TIMP1 and HA.

12. The method of claim 10, wherein the at least two diagnostic markers are TIMP1 and PIIINP.

13. The method of claim 10, wherein the at least two diagnostic markers include TIMP1, HA, and PIIINP, and wherein step (d) is further defined as combining the measured values ​​of the three diagnostic markers using a mathematical algorithm to obtain an IPF score.

14. The method of claim 10, wherein the IPF score is used to support, predict or replace the histological score of lung biopsy.

15. The method of claim 10, wherein the mathematical algorithm is a discriminant function algorithm. The method of claim 15 , wherein the discriminant function algorithm is a linear discriminant function algorithm.

17. The method of claim 10, wherein the IPF score is at least one factor in determining a treatment strategy for the individual.

18. The method of claim 10, wherein the IPF score is at least one factor used to monitor the efficacy of a treatment strategy implemented for the individual.

19. The method of claim 10, wherein the IPF score is at least one factor used to determine whether the individual should undergo a lung biopsy.

20. The method of claim 10, wherein the IPF score is at least one factor used to assess the extent of IPF in the individual.

21. A non-transitory computer readable medium comprising executable instructions which, when executed, cause a processor to perform operations comprising the method of any one of claims 1-20.

22. A composition comprising: (a) one or more IPF biomarkers, wherein the one or more IPF biomarkers include: Tissue inhibitor of metalloproteinase 1 (TIMP1), hyaluronic acid (HA) and type III procollagen N-terminal propeptide (PIIINP) or a combination thereof; as well as (b) one or more anti-IPF biomarker agents, wherein the one or more anti-IPF biomarker agents include: an anti-TIMP 1 agent, an anti-HA agent, an anti-PIIINP agent, or a combination thereof.

23. A kit for detecting IPF, the kit comprising: (a) one or more anti-IPF biomarker agents, wherein the one or more anti-IPF biomarker agents comprise: (i) anti-TIMP1 agents, (ii) anti-HA agents, (iii) anti-PIIINP agents, (iv) any combination thereof; and (b) Instructions for use.

24. A kit for detecting IPF, the kit comprising: (a) one or more anti-IPF biomarker agents, wherein the one or more anti-IPF biomarker agents include (i) an anti-TIMP1 agent and an anti-HA agent, (ii) an anti-PIIINP agent and an anti-TIMP1 agent, or (iii) an anti-HA agent, an anti-PIIINP agent, and an anti-TIMP1 agent; and (b) Instructions for use.

25. A kit comprising: (a) one or more anti-IPF biomarker agents, wherein the one or more anti-IPF biomarker agents include an anti-TIMP 1 agent, an anti-HA agent, and an anti-PIIINP agent; and (b) Instructions for use.

26. The kit of any one of claims 23-25, wherein the one or more anti-IPF biomarker agents comprise one or more antibody agents.

27. The kit of claim 26, wherein the one or more antibody agents are labeled with a detectable moiety.

28. The kit of claims 23-27, further comprising one or more control samples.

29. The kit of claim 28, wherein the control sample comprises one or more IPF biomarker standards.

30. Use of a kit according to claims 23-29 in an in vitro diagnostic assay for diagnosing IPF in a subject.

Citation Information

Cited By

  • Biomarker combination for in-vitro auxiliary diagnosis of idiopathic pulmonary fibrosis and application thereof

    CN122564108A